Please login to the form below
Fotivda
This page shows the latest Fotivda news and features for those working in and with pharma, biotech and healthcare.
Aveo’s tivozanib is knocked back by FDA once again
EMA to approve the drug as Fotivda in Europe in 2017 based on the TIVO-1 data. ... Fast forward a few years , and Fotivda’s license in Europe is at risk of being withdrawn, and the company’s attempt to file in the US based on TIVO-3
Latest news
-
AVEO warns EU approval of Fotivda could be at risk
Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of ... revealed a hazard ratio (HR) of 1.12 for Fotivda, in
-
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug
EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib).
-
NICE backs EUSA's RCC treatment Fotivda
14% of patients on Fotivda requiring a dose reduction due to adverse events compared to the 43% on Nexavar. ... However, Aveo Oncology is looking to re-file Fotivda in the US pending the results of the TIVO-3 study.
-
EUSA receives European green light for kidney cancer treatment Fotivda
European Commission approves the drug to treat RCC. The European Commission (EC) has approved EUSA Pharma’s vascular endothelial growth factor receptor (VEGFR) inhibitor Fotivda (tivozaniv) as a first-line treatment
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
got the okay for VEGF receptor inhibitor Fotivda (tivozanib) for the treatment of advanced renal cell carcinoma.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Latest appointments
-
EUSA Pharma appoints Rolf Hoffmann to its board
Fotivda in Europe.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
No results were found
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
